IMPORTANCE Cervical cancer can be prevented with detection and treatment of precancerous cell changes caused primarily by high-risk types of human papillomavirus (hrHPV), the causative agents in more than 90% of cervical cancers.
H igh-risk human papillomavirus (hrHPV) is readily transmitted through sexual contact 1, 2 and is recognized as a causative agent in more than 90% of cervical cancers. 3 Persistent infection with hrHPV types 16 and 18 is responsible for most cases. 4, 5 Although a high proportion of sexually active women become infected with some human papillomavirus type by age 25 years, most infections resolve spontaneously. 6 Effective screening and treatment for precancerous lesions are associated with low rates of cervical cancer mortality in the United States. 7 Annual age-adjusted cervical cancer incidence in the United States was 7.4 cases per 100 000 women and mortality was 2.3 deaths per 100 000 women (2011) (2012) (2013) (2014) (2015) , with the highest incidence among black (8.4 per 100 000) and Hispanic (8.9 per 100 000) women. Black women also had the highest mortality rate (3.7 deaths per 100 000 women). 8 In 2012, the US Preventive Services Task Force (USPSTF) recommended screening women aged 21 to 65 years for cervical cancer with cytology (Papanicolaou [Pap] smear) every 3 years, with an option for women 30 years and older for hrHPV cotesting (cytology and cervical swab for hrHPV) every 5 years (A recommendation). 9 This systematic review, conducted to update evidence on cervical cancer screening, focused on the effectiveness of hrHPV screening strategies relative to cytologybased screening to support an updated USPSTF recommendation.
Methods

Scope of Review
Cytology is the foundation for long-standing cervical cancer screening recommendations, with well-established benefits and harms. The USPSTF commissioned this review to evaluate direct evidence from trials and large observational cohort studies on the comparative effectiveness of screening approaches that use hrHPV screening. Specifically, the 2 key questions (KQs) ( Figure 1 ) aimed to identify the benefits (KQ1) and harms (KQ2) of cervical cancer screening using hrHPV screening alone as the initial test (primary screening) or paired with cytology (cotesting), compared with screening with cytology as the primary test. Additional methodological details regarding the review search strategies, including detailed study inclusion criteria, excluded studies, and description of data analyses, are available in the full evidence report at https://www.uspreventiveservicestaskforce.org/Page /Document/UpdateSummaryFinal/cervical-cancer-screening2.
Data Sources and Searches
Comprehensive literature searches were performed for primary literature in MEDLINE, PubMed, PsycINFO, and the Cochrane Collaboration Registry of Controlled Trials from January 2011 through February 15, 2017 , bridging from the dates of the previous USPSTF review. 11 Database searches were supplemented with experts' suggestions and by reviewing reference lists from other relevant systematic reviews. After February 2017, ongoing surveillance continued through article alerts and targeted searches of high-impact journals to identify major studies published in the interim that could affect the conclusions or understanding of the evidence and the related USPSTF recommendation. The last surveillance was conducted on May 25, 2018 , and resulted in the addition of the initial results of the Compass trial. 12 The final results of the HPV FOCAL trial, published in JAMA in July 2018, have also been incorporated in this review. 13 
Study Selection
Two reviewers independently reviewed 2972 unique citations and 164 full-text articles against specified inclusion criteria ( Figure 2 ). Discrepancies were resolved through consensus and consultation with a third investigator when required. Eligible studies were rated as fair or good quality, published in English, and conducted in highly developed countries. 15 Quality assessment criteria are reported in eTable 1 in the Supplement. Studies had to be conducted in primary care or generalizable settings (eg, family planning clinics); studies based on laboratory results alone without an identified cohort were excluded. Randomized clinical trials (RCTs), individual participant data (IPD) meta-analyses, systematic reviews, and large ( Ն 10 000 women) longitudinal cohort studies that examined the benefits or harms of primary hrHPV screening or cotesting among average-risk women 21 years and older were included. Studies in women without a cervix, at high risk for cervical cancer, or who were pregnant were excluded. Studies evaluating hrHPV as a triage test after cytology compared with cytology alone were excluded. Cohort studies including fewer than 10 000 women were excluded, unless they addressed a subpopulation of interest (eg, underscreened women). Invasive cervical cancer generally develops over years, preceded by progressive precancerous changes of the cervix, defined as cervical intraepithelial neoplasia (CIN) categorized as CIN 1, CIN 2, and CIN 3. 16 For KQ1, because invasive cervical cancer is a rare event in countries with organized screening programs such that even large trials did not have sufficient sample size or duration to detect changes in invasive cervical cancer incidence, CIN 3 or worse (CIN 3+) was chosen as the primary outcome. CIN 3+ was consistently reported because of broad consensus that detection and treatment of CIN 3 can prevent progression to invasive cervical cancer. For KQ2, studies were included if they reported false-positive CIN 2+ or falsenegative invasive cervical cancer screening test results; biopsy rates, colposcopy rates, or both; or psychological harms (eg, labeling, stigma, distress, quality of life).
Data Extraction and Quality Assessment
Two investigators independently assessed the quality of included studies using USPSTF design-specific criteria for RCTs 17 and the Newcastle-Ottawa Scale for observational studies. 18 Each study was rated as good, fair, or poor (eTable 1 in the Supplement). Disagreements in quality ratings were resolved by consensus and by consultation with a third investigator if required. Poor-quality studies with major flaws (eg, attrition >40%, differential attrition >20%) or multiple important limitations that could invalidate the results were excluded. One investigator extracted study-level data (study design details, population and intervention characteristics, outcomes) into standardized evidence tables and a second investigator confirmed the accuracy of the data.
Data Synthesis and Analysis
Because of the heterogeneity of screening tests, screening protocols, follow-up protocols, and settings, results were qualitatively synthesized. Summary tables of study design, population characteristics, protocols, and intervention and follow-up details for each round of screening were created. Results were synthesized by KQ and screening strategy, either primary hrHPV screening or cotesting. When possible, results were also stratified by age (<30-35 years vs Ն30-35 years) because of lower prevalence of hrHPV in women 30 years and older. Results were based on a "number of women screened" denominator, rather than intention-to-treat calculations using all women randomized. Relative risks (RRs) and 2-sided 95% confidence intervals were calculated when not reported in the study. Stata version 15.1 (StataCorp) was used for all analyses. To estimate potential harms or burden of screening, test positivity, colposcopy rates, and false-positive rates were reported or calculated from available data. The false-positive rate was reported to quantify the extent to which women in a cervical cancer screening program experienced positive screening test results necessitating further follow-up (ie, triage testing, repeat screening, colposcopy, and biopsy) and were not found to have precancerous lesions or cervical cancer (ie, CIN 2+). This was calculated as the number with a positive screening test result without diagnosis of CIN 2+ as a proportion of women screened who were not diagnosed with CIN 2+. This pragmatic definition relies on colposcopy as a reference standard, recognizing that there is variability in the accuracy of colposcopy and biopsy. 19 False-negatives were defined as the proportion of invasive cervical cancer cases occurring among women with negative preceding screening results. Psychological harms, including adverse effects on anxiety, distress, and sexual satisfaction, were abstracted when reported.
Results
Effectiveness of Screening
Key Question 1. What is the effectiveness of human papillomavirus for hrHPV testing, with or without cytology, as a primary screening strategy for reducing cervical cancer mortality and incidence compared with currently recommended screening strategies for women in the United States? Four fair-or good-quality cervical cancer screening RCTs were identified that compared primary hrHPV screening with cytology (n = 282 838), [12] [13] [14] [19] [20] [21] [22] [23] and 4 RCTs compared cotesting with cytology (n = 127 717) ( Table 1) . 14, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] One IPD meta-analysis combined 176 464 women from 1 primary hrHPV screening trial and 4 hrHPV cotesting trials to examine invasive cervical cancer incidence.
47
Four large cohort studies were included: 1 of primary hrHPV screening (n = 48 736), 24 2 of cotesting (n = 351 613), 36-42,48,49 and 1 reporting on cotesting outcomes in 1832 unscreened women.
42
Trials varied in the number of reported screening rounds (1 or 2), the screening interval (3-5 years), consistency between screening rounds (eg, randomization maintained, cytology only or cotesting for both intervention and control groups in the second screening round), and the protocols for evaluation of abnormal screening results. For primary hrHPV screening, follow-up varied and included cytology triage from a specimen obtained at the time of initial screening and held, hrHPV genotyping with follow-up based on viral type, or immediate colposcopy (Table 1) . Four RCTs offered consistent evidence that primary hrHPV screening will detect Table 2) . 12, 13, 19, 21, 22 The New Technologies for Cervical Cancer (NTCC) Phase II trial of primary hrHPV screening (in which all women with a positive hrHPV test result were referred to colposcopy) had complete results from 2 rounds of screening, but the screening strategy was not maintained (at round 2 screening, all women received cytology testing). 14, 20 In that study, CIN 3+ detection in round 1 was 3 times higher in the hrHPV screening group, with cumulative detection 1.8 times higher after the second round of screening. In the recently published 48 -month screening results of the HPV FOCAL trial, all women received cotesting at the second round of screening. 13 Amsterdam (POBASCAM) trial reported 14 years of follow-up tracked through the nationwide network and registry of histopathology and cytopathology. 29 In both studies, no statistical difference in cumulative CIN 3+ rates was detected between the intervention and control groups. Two large single-group cohort studies of cotesting showed higher detection of CIN 3+ in the first screening round relative to a follow-up round (eTable 2 in the Supplement). 24, 37, 43, 44 Long-term evaluation of the US-based cohort found that risk of CIN 3+ in women cotesting negative was very low 3 and 5 years after testing (0.06% and 0.1%, respectively).
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To examine the effect of hrHPV screening on invasive cervical cancer in cervical cancer screening trials, Ronco et al conducted an IPD meta-analysis of 5 trials: 4 trials of cotesting and a single trial of primary hrHPV screening (NTCC Phase II). 47 Participant data were pooled, although these trials had distinctly different screening protocols, screening intervals, and hrHPV test types. The IPD metaanalysis included 176 464 women with 1 214 415 person-years of follow-up, with a total of 107 cases of invasive cervical cancer in a median follow-up period of 6.5 years. Cumulative detection of invasive cervical cancer was 46.7 per 100 000 in the hrHPV-screened women, compared with 93.6 per 100 000 women in the cytology groups.
With a random-effects model, the overall pooled rate ratio for invasive cervical cancer in the hrHPV-screened women was 0.61 (95% CI, 0.41-0.91). The I 2 test for statistical heterogeneity was not significant (0.0%, P = .52). Key Question 1a. Does the effectiveness of hrHPV testing to reduce cervical cancer outcomes vary by subpopulation (eg, age, race/ ethnicity, screening history, hrHPV immunization status, and socioeconomic status)?
No trials provided data on race/ethnicity, screening history, or socioeconomic status for primary hrHPV screening. Several studies reported on outcomes by age group (eTables 3 and 4 in the Supplement), and 1 study reported on outcomes by age corresponding to the introduction of a population-based hrHPV immunization program. 12 One cohort study reported outcomes of a single round of cotesting in underscreened women.
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Primary hrHPV Compared With Cytology Screening Stratified by Age
In 4 trials of primary hrHPV screening, first-round CIN 3+ detection with hrHPV screening was consistently higher (range, 0.6% 14,20 to 2.4% 13, 19, 21, 22 ) among women younger than 35 years (eTable 4 in the Supplement) than for women older than 35 years (range, 0.2% 23 to 0.5% 13, 19, 21, 22 ) (eTable 3 in the Supplement).TheRRforCIN3+de-tection between screening groups, however, was similar to the overall findings in both the younger (<30-35 years) and older (Ն30-35 years) age groups. In the Compass trial, 12 participants were recruited from a population having 70% hrHPV vaccination coverage among women 33 years and younger. Primary hrHPV screening detected higher rates of CIN 3+ compared with cytology for both the younger (25-33 years) and older (34-64 years) age groups. Absolute detection rates were higher for women younger than 30 to 35 years, regardless of the screening test, in all primary hrHPV screening trials. In summary, while risks of hrHPV-positive results were consistently higher in women younger than 30 to 35 years, in most studies differences in CIN 3+ detection between screening methods were consistent across age groups.
Screening With hrHPV Cotesting in Underscreened Populations
A prospective single-cohort study from Spain described the outcomes of initial cotesting in a cohort of 1832 women older than 39 years with no documented cervical cancer screening in the previous 5 years. 42 Table 2) . 13 The POBASCAM trial with 5-year screening intervals exhibited CIN 3+ detection and RRs for cotesting similar to those reported in cotesting trials with 3-year screening intervals. [27] [28] [29] In 13-to 14-year follow-up of the Swedescreen and POBASCAM trials, CIN 3+ risk remained persistently low in women who tested hrHPV-negative on initial screening, suggesting that 5-year intervals for hrHPV screening are no less effective than 3-year intervals over longer time frames. 29, 31 Recently published analyses of the large US-based cotesting cohort 48 
Primary hrHPV Screening
Trial differences in the protocol for follow-up of positive hrHPV screening test results affected colposcopy and false-positive rates.
In the NTCC Phase II protocol, all hrHPV-positive results were referred directly to colposcopy. 14, 20 Accordingly, the false-positive rate for CIN 2+ was higher with hrHPV screening (7.4% vs 3.2%), as was the colposcopy rate (7.9% vs 2.8%), than with cytology screening in the trial ( Table 3) . Most women referred to colposcopy underwent the procedure (93.6% in the intervention group, 90.6% in the control group), and more women in the hrHPV screening group underwent biopsy (3.2% vs 1.3% in the control group). The HPV FOCAL trial used a liquid-based cytology triage strategy for hrHPV-positive results. 13, 19, 21, 22 In round 1 of screening, 5.7% of women in the hrHPV testing group were referred to colposcopy, compared with 3.1% in the cytology-only control group, and 94.1% of the trial participants referred to colposcopy attended. 13 Colposcopy referral rates in round 1 of the Compass trial for hrHPV screening compared with cytology screening were 3.8% vs 2.7%. 12 In the FINNISH trial, 23 primary hrHPV screening false-positive rates (7.2%) and colposcopy referral rates (1.2%) were similar to cytology screening false-positive (6.5%), and colposcopy referral (1.1%) rates. In 3 trials reporting age-stratified results, colposcopy referrals in round 1 of screening for women younger than 30 to 35 years ranged from 2.3% to 13.1% with hrHPV testing, compared with a range from 1.9% to 4.7% for cytology screening (eTable 7 in the Supplement). Among women older than 30 to 35 years, colposcopy referrals ranged from 0.9% to 5.8% for hrHPV testing, compared with 1.0% to 2.5% for cytology screening (eTable 6 in the Supplement). False-negative results for invasive cervical cancer (based on interval detection) were uncommon. The NTCC Phase II trials reported no CIN 3 or invasive cervical cancer cases among screennegative women in either group in follow-up after the first round of screening (3.5 years maximum). 14, 20 The larger FINNISH trial reported invasive cervical cancer among screen-negative women in 0.01% (5/57 135) of the hrHPV testing intervention group participants and 0.003% (2/61 241) of the cytology control group participants after 1 round of screening with 5 years of follow-up. 23 Data on invasive cervical cancer among screen-negative women were not available for the HPV FOCAL or Compass trials. No studies reported on the psychological effects of primary hrHPV screening.
hrHPV Cotesting
Colposcopy rates were reported in only 2 trials of cotesting (ARTISTIC and NTCC Phase I) ( Table 3) . [32] [33] [34] [35] In the ARTISTIC trial, higher falsepositive rates were observed with cotesting relative to the cytology screening control group at round 1 (19.9% vs 10.9%) and round 2 (11.2% vs 4.6%). Colposcopy rates in round 1 were 6.8% in the cotesting group and 5.2% in the cytology group. [32] [33] [34] [35] The proportion of women attending colposcopy and undergoing biopsy was not reported. Only the NTCC Phase I trial reported age-stratified colposcopy and false-positive rates. In that trial, hrHPV-positive women 35 years and older and those with results positive for atypical squamous cells of undetermined significance were referred directly to colposcopy; colposcopy rates were 3 times higher for cotesting compared with cytology (10.6% vs 3.0%). 14, 25, 26 Of those referred, 94%
in the intervention group and 91% in the control group received a colposcopy. For the Swedescreen trial, 30,31 colposcopies were not reported and false-positive rates could not be calculated. The POBASCAM 27-29 trial did not report colposcopy rates, but falsepositive rates were twice as high with cotesting (5.8% vs 2.6%) at round 1 and similar at round 2, in which both the intervention group and the control group received cotesting (6.4% vs 6.5%).
The IPD meta-analysis obtained additional data from 5 trials (4 trials of cotesting and a single trial of primary hrHPV screening) and reported similar overall biopsy rates for women assigned to hrHPV cotesting or primary testing compared with cytology in analysis of the POBASCAM, Swedescreen, and ARTISTIC trials, which had a fixed-effects pooled rate ratio for biopsy of 1.02 (95% CI, 0.97-1.07; I 2 =30.7%;P = .24). A pooled estimate calculated with the NTCC trial biopsy rate included had unacceptably high statistical heterogeneity (I 2 = 99.1%; P < .001). The rate ratio for biopsy from the NTCC trials was 2.24 (95% CI, 2.09-2.39) with hrHPV testing, likely because of the direct-to-colposcopy triage protocol. 47 False-negative rates were difficult to estimate. No invasive cervical cancer cases were observed in screen-negative women in either screening group in 2 studies, 14, 25, 26 ,32-35 and 1 did not report rates of invasive cervical cancer among screen-negative women. 30, 31 In the POBASCAM trial, 1 case of invasive cervical cancer was detected in a screen-negative woman in the control group and no cases in the intervention group, with 4 years follow-up on the first screening round. [27] [28] [29] In 14 years of long-term follow-up, there were no statistically significant differences in incidence of invasive cervical cancer among women in the intervention group who screened hrHPV-negative and cytology-normal at baseline and among those in the control group with normal cytology findings at baseline. 29 Findings of a large US-based cohort of women who received cotesting suggested that hrHPV testing has few false-negative cases of CIN 3+ detected by cytology: the 5-year risk of CIN 3+ was 0.12% (95% CI, 0.11%-0.12%) for women testing hrHPV-negative, compared with 0.10% (95% CI, 0.09%-0.10%) for women with negative cotesting results.
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Estimates of colposcopy rates from large observational cohort studies were similar to or lower than those observed in trials (eTable 5intheSupplement). Just more than 6% of women were referred jama.com to colposcopy over 2 rounds of hrHPV primary screening in an Italian cohort study (n = 48 751). 24 In a German study of hrHPV cotesting (n = 19 795), 3.9% of women were referred to colposcopy at the first round of screening and 1% at a second round.
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Two included studies reported psychological effects of hrHPV cotesting. 32, 45 In a substudy of the ARTISTIC trial, 45 samples of women aged 20 to 64 years were surveyed approximately 2 weeks after receiving screening results (n = 2508). Women assigned to the study intervention screening group who received hrHPV results in addition to their cytology screening results reported lower sexual satisfaction but similar levels of distress and anxiety in the short term.
A smaller cross-sectional study (n = 428) by McCaffery et al 45 surveyed women 1 week after they received cervical cancer screening results and found that for women who underwent cotesting and had normal cytology findings, those with hrHPV-positive results were more distressed and anxious than women with hrHPV-negative results and had worse feelings about their current, past, and future sexual partners regardless of cytology results. Key Question 2a. Do the adverse effects vary by subpopulation (eg, age, race/ethnicity, and hrHPV immunization status)? Three primary hrHPV screening trials and 1 cotesting trial reported age-stratified colposcopy rates (eTables 6 and 7 in the Supplement). In all trials, women younger than 30 to 35 years screened with primary hrHPV testing or cotesting had higher referral rates for colposcopy (range, 2.3%-13.1%) than women screened with cytology (range, 1.9%-4.7%). 14, 20, 22, 23 In the Compass trial of primary hrHPV screening, colposcopy referrals were higher with hrHPV screening among women aged 25 to 33 years (8.5% in the intervention group vs 4.7% in the control group) and lower for women aged 34 to 64 years (2.6% in the intervention group vs 2.2% in the control group) in both screening groups, despite expected vaccination rates in younger women of approximately 70%.
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Key Question 2b. Do adverse effects vary by screening strategy, including by rescreening interval? The influence of screening interval and strategy on potential harms of missed cancer cases or possible overdetection could not be directly ascertained from available evidence because of lack of within-trial interval comparisons and variability of protocols across studies. Screening intervals of included trials ranged from 2 to 5 years, with the longest intervals from FINNISH 23 and POBASCAM.
27-29
The trials with longer intervals reported some invasive cervical cancer cases among women who had tested hrHPV-negative, but these trials (FINNISH and POBASCAM) also had larger samples and there were very few invasive cervical cancer cases overall, limiting inferences that can be drawn from between-study comparisons. After 2 negative cotesting results, rates of invasive cervical cancer in the US-based cohort were very low (0.003% [95% CI, 0.002%-0.006%]) and equal at 3-and 5-year screening intervals.
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Discussion A summary of the evidence for this review is shown in Table 4 . Four RCTs of primary hrHPV screening and 4 of cotesting (both hrHPV testing and cytology) compared the use of hrHPV screening for cervical cancer screening with cytology alone for the detection of CIN 3+ and invasive cervical cancer. The evidence was consistent across trials that primary hrHPV screening increased detection of CIN 3+ in the initial round of screening by as much as 2 to 3 times when compared with cytology. Evidence was mixed in cotesting trials; CIN 3+ detection in round 1 was not significantly higher for cotesting. No trials compared hrHPV primary testing with cotesting. Evidence on subgroups was limited to age and a single-cohort study focused on previously underscreened women. Women younger than 35 years had consistently higher rates of hrHPV positivity and of CIN 3+, but the RR of CIN 3+ detection with primary hrHPV screening or cotesting compared with cytology was similar between younger and older women. False-positive rates were higher in the intervention group for both primary hrHPV screening and cotesting in the first screening round. Colposcopy referrals were often reported but biopsy rates were not, limiting estimation of the downstream harms of screening. In 3 primary hrHPV screening trials and all cotesting trials, rates of colposcopy referral were higher in the intervention group, indicating a greater relative burden with hrHPV screening and potential differences in downstream consequences of treatment compared with screening cytology. Harms of treatment of the cervix to remove precancerous cells were not reported in any of the included studies but include pain and bleeding, which on rare occasion requires vaginal packing or transfusion.
52,53 Harms related to subsequent pregnancy outcomes, particularly risk of secondtrimester pregnancy loss and preterm birth, may occur after cold knife conization or loop electrosurgical excision procedure deeper than 10 mm. 54,55 Limited evidence suggested that, compared with abnormal cytology results, hrHPV test positivity may be associated with greater short-term psychological harm.
32-35
Cervical cancer incidence and mortality have substantially decreased since the introduction of screening programs more than half a century ago; the lowest rates are found in countries with organized screening programs. All of the RCTs included in this review were conducted in countries with robust, organized screening programs. Organized screening programs are well-suited for comparative trials of screening strategies; however, the generalizability of findings from this review to women in the United States is limited by the lack of organized screening programs for the majority of US-based women. Most cervical cancer screening in the United States is opportunistic, without population-based registries or regular invitations to screening. More than 50% of women diagnosed with cervical cancer in the United States have not been screened in the prior 3 to 5 years. 56 The highest proportions of unscreened women are those without insurance (23.1%) or no regular clinician (25.5%).
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Cervical cancer predominantly affects underscreened women in the United States; thus, a substantial effect on cervical cancer incidence and mortality requires the identification of effective outreach strategies. Limited evidence from a single cohort study of poorly screened women in Spain suggests that the increased sensitivity of hrHPV screening may be particularly important for early detection among underscreened women. 42 Several systematic reviews summarize evidence that hrHPV screening via self-collection of samples may be a sufficiently accurate and acceptable strategy for reaching underscreened and unscreened populations. 10, 58, 59 Further research is needed to examine the effect of self-collection screening strategies on overall screening rates, adherence to follow-up, and health outcomes for women with limited access to health care or low rates of participation in screening programs. Three RCTs reported on women <35 y CIN 3+ detection rates were comparable between the intervention and control groups for both rounds, with no significant differences in cumulative CIN 3+ detection Detection rates ranged from 0.1%-3.3% across trials
Mortality data not reported
Reasonably consistent and precise for CIN 3+ detection over 1-2 rounds of screening Imprecise for invasive cervical cancer incidence
Randomization not maintained for more than 1-2 rounds of screening; heterogeneity in screening and follow-up tests and protocols; trials underpowered to assess invasive cervical cancer incidence and mortality Single-cohort study with no comparison group 
Limitations
This review was limited by the quality and heterogeneity of the included studies. First, the quality of many of the included studies was rated as fair because of problems with attrition, protocol changes, and lack of blinding of outcome assessment. Second, the overall body of evidence was limited by trials having no more than 2 and often only 1 randomized round of screening available for comparisons. Only 1 trial (ARTISTIC) maintained the same strategy over 2 rounds of screening. [32] [33] [34] [35] Third, outcome reporting on colposcopy and biopsy rates was inconsistent, and none of the trials reported on adverse events associated with the screening tests or with diagnostic and treatment procedures resulting from screening. Fourth, the trial evidence was supplemented with results of large cohort studies of primary hrHPV screening or cotesting over 2 screening rounds; however, none of the cohort studies had a comparison group screened with cytology only.
Conclusions
Primary hrHPV screening detected higher rates of CIN 3+ at firstround screening compared with cytology. Cotesting trials did not show initial increased CIN 3+ detection. Both hrHPV screening strategies had higher false-positive and colposcopy rates than cytology, which could lead to more treatments with potential harms. Cohort studies, adapted from the Newcastle-Ottawa Scale
• Was there representativeness of the exposed cohort?
• Was the non-exposed systematic selected?
• Was the ascertainment of exposure reported? • Were eligibility criteria specified?
• Were groups similar at baseline?
• Was the reading (interpretation) of the pathology results adequate?
• Were outcome assessors blinded?
• Were measurements equal, valid and reliable?
• Was follow-up long enough for outcomes to occur?
• Were the statistical methods acceptable?
• Was the handling of missing data appropriate?
• Was there adjustment for confounders?
• Was there acceptable follow-up?
Good quality studies generally meet all quality criteria. Fair quality studies do not meet all the criteria but do not have critical limitations that could invalidate study findings. Poor quality studies have a single fatal flaw or multiple important limitations that could invalidate study findings. Critical appraisal of studies using a priori quality criteria are conducted independently by at least two reviewers. Disagreements in final quality assessment are resolved by consensus, and, if needed, consultation with a third independent reviewer.
